Metrics as of 10/16/2026, 09:46 AM (Berlin time), refresh in progress.
Eledon Pharmaceuticals Stock
Eledon Pharmaceuticals, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- David-Alexandre C. Gros
- Employees
- 33
- Market cap
- $184 M
- IPO
- 17/09/2014
- Web
- eledon.com
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating innovative treatments for individuals battling autoimmune disorders, amyotrophic lateral sclerosis (ALS), and those undergoing organ or cell transplantation. Their flagship therapeutic candidate, AT-1501, is a humanized…
Eledon Pharmaceuticals stock: price history
1D
+0.9%
1W
-6.2%
1M
-16.2%
6M
-39.1%
YTD
+50.3%
1Y
-17.2%
2Y
-23.1%
5Y
-59.7%
10Y
-99.2%
Next earnings date
Next earnings date
13/11/2026 (in 27 days)
Volatility around earnings
~29% weaker price swings than usual
Ask the agents about Eledon Pharmaceuticals
Analyst assessment of Eledon Pharmaceuticals
PRICE TARGET LOW
US$5.00
CONSENSUS
US$7.00
MEDIAN
US$7.00
PRICE TARGET HIGH
US$9.00
0
STRONG BUY
4
BUY
0
HOLD
0
SELL
0
STRONG SELL
4
TOTAL · Buy
As of: 18/11/2025
Eledon Pharmaceuticals stock metrics
P/E
-2.29
P/B
3.58
EV/EBITDA
-2.2
RETURN ON EQUITY
-43.9%
NET MARGIN
0.0%
DEBT/EQUITY
0.01
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
91.8%
FLOAT SHARES
74,596,112
AVG. DAILY VOLUME (30D)
841,960
Insider transactions (SEC)
Perrin Steven
Perrin Steven
Gros David-Alexandre C
Gros David-Alexandre C
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Eledon Pharmaceuticals stock
What does Eledon Pharmaceuticals do?
Eledon Pharmaceuticals, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is David-Alexandre C. Gros, the company employs around 33 people.
The IPO was on 17/09/2014; the stock trades on NASDAQ under the ticker ELDN.
What do analysts say about Eledon Pharmaceuticals stock?
4 analysts rate the stock, the consensus is Buy (as of 18/11/2025).
The average price target is US$7.00, ranging from US$5.00 to US$9.00, with a median of US$7.00.
This is an external assessment, not a statement by Market Jury.
When does Eledon Pharmaceuticals report next?
The next earnings date is 13/11/2026.
Around past earnings, price swings were roughly -29% stronger than usual.
Does Eledon Pharmaceuticals pay a dividend?
No, Eledon Pharmaceuticals currently does not pay a dividend.
Which stocks are comparable to Eledon Pharmaceuticals?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Eledon Pharmaceuticals stock analyzed?
Clicking "Analyze stock" lets five strategies assess Eledon Pharmaceuticals against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.